A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
M Michael, N Pavlakis, P Clingan, R De Boer, M Johnston, S Clarke
Oncology Reports: an international journal devoted to fundamental and applied research in oncology | SPANDIDOS PUBL LTD | Published : 2012
The authors would like to thank all study investigators, coordinators and patients who participated in the FiGhT study. We would also like to thank Kate Jin, Vita von Neumann-Cosel and the Roche study team. Medical writing assistance was provided by Joseline Ojaimi from Roche Products. The FiGhT study was sponsored by Roche Products Australia.